Latest from SCCA

David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses responses to the chimeric antigen receptor (CAR) T-cell product JCAR017.
 
Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
While chemotherapy has historically been used to treat patients with Merkel cell carcinoma, immunotherapy advances have infused new hope into the treatment landscape.
Defined composition CAR T cells directed against CD19 have potent anti-tumor activity in B cell malignancies, including acute lymphocytic leukemia.
Lymphoma physician-scientist, leader and mentor made lifesaving contributions to the development of targeted cancer therapies.
Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.
Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.
Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer.
Publication Bottom Border
Border Publication
x